- Home
- PSHG vs NRSN Comparison
PSHG vs NRSN Comparison
Compare PSHG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | NRSN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | Greece | Israel |
| Employees | N/A | 15 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 24.4M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSHG | NRSN |
|---|---|---|
| Price | $1.80 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 72.7K | ★ 98.8K |
| Earning Date | 05-26-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | $583.67 |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.63 |
| 52 Week High | $2.58 | $2.60 |
Technical Indicators
Market Signals| Indicator | PSHG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 50.72 |
| Support Level | $1.79 | $0.68 |
| Resistance Level | $2.05 | $0.86 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.68 | 52.07 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.